A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs Carotuximab (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms AVANTE
- Sponsors Santen Pharmaceutical
- 04 Feb 2019 Planned number of patients changed from 56 to 76.
- 04 Feb 2019 Planned End Date changed from 1 Jul 2019 to 1 Jan 2020.
- 04 Feb 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.